Johnson & Johnson's (JNJ) Pharmaceuticals Business Review is just getting underway (webcast) (agenda) (presentation). The company anticipates more than 10 new product filings and 25 significant brand extensions by 2017. Shares -1.2% premarket.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs